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Background: No surveys of stress ulcer prophylaxis prescribing in the USA
have been conducted since 1995. Since that time, the most comprehensive
meta-analysis and largest randomized study to date concerning stress ulcer
prophylaxis have been published.
Results: Three hundred sixty-eight surveys were sent to all members of the
Section of Pharmacy and Pharmacology of the Society of Critical Care Medicine.
One hundred fifty-three (42%) surveys were returned. Representatives from 86%
of institutions stated that medications for stress ulcer prophylaxis are used in a
majority (>90%) of patients admitted to the intensive care unit (ICU). Twenty-
two per cent of institutions have recommendations for both ICU and non-ICU
settings. Fifty-eight per cent of institutions stated that there was one preferred
medication for stress ulcer prophylaxis, and in 77% of these histamine-2-
antagonists were the most popular.
Conclusions: There are wide variations in prescribing practices for stress ulcer
prophylaxis. Institutions should consult published literature and use pre-existing
guidelines as templates for developing their own guidelines.
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Introduction
Stress-induced gastroduodenal erosions are a frequent
occurrence in critically ill patients, but it is the incidence of
clinically important complications resulting from these ero-
sions that is important in deciding which patients should
receive prophylaxis. Clinically important complications
include bleeding that requires transfusion, bleeding associ-
ated with hemodynamic instability, and gastrointestinal
perforations. Failure to document these complications in
published studies limits the conclusions that can be drawn
from much of the available literature. There have been
inconsistent results in those studies that did record clini-
cally important bleeding, depending on severity of illness
or injury, and concomitant or underlying disease states.
Because the results of clinical investigations have led to
different recommendations concerning stress ulcer pro-
phylaxis, Cook et al [1] performed a meta-analysis of ran-
domized trials to resolve the controversies associated
with previous research in this area. They concluded that
there was no clear agent of choice for prophylaxis based
on efficacy considerations (ie ability to prevent clinically
important bleeding), but sucralfate might have advan-
tages in terms of adverse effects because it was associated
with a lower incidence of pneumonia compared with hist-
amine-blocking medications. Within 2 years of the publi-
cation of this meta-analysis, Cook et al [2] reported their
findings from the largest randomized study conducted to
date concerning stress ulcer prophylaxis. In that study,
intravenous ranitidine 50mg/8h (with dose decreased for
renal dysfunction) was associated with a lower incidence
of clinically important bleeding compared with sucralfate
1g/6h (relative risk 0.44, 95% confidence interval
0.21–0.92,  P=0.02). There were no significant differences
ICU = intensive care unit.between the medications with respect to pneumonia or
mortality.
Given the recent publication of these important results,
the present survey was conducted by members of the
Research Committee of the Section of Pharmacy and
Pharmacology of the Society of Critical Care Medicine.
The survey was mailed to Section members who are well
versed in medications used in the critical care area. The
purpose of the survey was to determine current prescrib-
ing practices in light of recent publications concerning
stress ulcer prophylaxis. The survey was also intended to
assess institutional evaluations of stress ulcer prophylaxis.
It is hoped that the results of this survey will provide clini-
cians with information as to how their prescribing and
evaluation practices compare with those of practitioners in
other institutions. Additionally, the survey might uncover
institutional practices that are inconsistent with the avail-
able literature and that deserve further consideration.
Materials and methods
A survey was developed that contained questions regard-
ing institutional prescribing and evaluation of stress ulcer
prophylaxis. There were 11 questions on the survey,
although several of the questions asked for additional infor-
mation, depending on the initial response. The length of
the survey was a compromise between asking enough
questions to determine patterns of medication use and
evaluation without discouraging completion of the survey
by unnecessary length. The majority of questions were in a
‘yes/no’ format with further information required on the
basis of the initial response. For example, one question was
‘Does your institution have written guidelines for stress
ulcer prophylaxis?’ If the answer to this question was ‘yes’,
then the responder was asked an additional series of ques-
tions concerning the details of these guidelines.
Several of the questions requested information that
required answers as a percentage value. For example,
‘What percentage of patients discharged from the inten-
sive care unit to non-intensive care unit settings remain on
stress ulcer prophylaxis?’ For this type of question, the
responder was requested to select from a range of percent-
ages, such as 0–25%, 26–50%, 51–75%, or 76–100%. Most
of the remaining questions allowed answers in either a
check box or free text format.
A series of steps were taken in order to improve the valid-
ity and reliability of the instrument. After the initial survey
construction at one site, the instrument was distributed to
selected members of the Section of Pharmacy and Pharma-
cology of the Society of Critical Care Medicine for pretest-
ing of the instrument. Additionally, a physician who
practices in the critical care setting (but is not a member of
the Section) was asked to review the instrument. Changes
were made to the document on the basis of this input.
The survey was sent to all members of the Section of
Pharmacy and Pharmacology of the Society of Critical
Care Medicine in the fall of 1998. A stamped, self-
addressed envelope was included in the mailing for
returning the completed surveys. Descriptive statistics
were used to analyze and report the data, because the
answers were not amenable to inferential testing. Data
were recorded and analyzed using Microsoft Excel version
4.0 (Microsoft Corporation).
Results
A total of 368 surveys were distributed and 153 were
returned, yielding a response rate of 42%. Of the hospitals
surveyed 62% had more than 400 beds, and 32% had
between 200 and 399 beds. Sixty-one per cent of institu-
tions had more than 40 intensive care unit (ICU) beds and
29% had between 20 and 39 beds. It is difficult to
comment on the focus of the ICUs (ie surgical, medical,
mixed or special) because of many respondents checking
more than one item. Sixty-one per cent were classified as
level I trauma centers. Of institutions 86% stated that med-
ications for stress ulcer prophylaxis are used in a vast
majority (>90%) of patients admitted to the ICU. Twenty-
two per cent have recommendations for both ICU and non-
ICU settings. These differences are provided in Table 1.
The majority of questions on the survey pertained to
stress ulcer prophylaxis from an overall institutional stand-
point. There were a few questions, however, that
attempted to define specialized populations at the institu-
tions that might be at particular risk for stress ulceration
and related complications. With the exception of multiple
trauma, these injuries can be considered as ‘single-system’
problems. The number of institutions that routinely insti-
tute stress ulcer prophylaxis in these specialized popula-
tions is listed in Table 2.
Twenty-seven per cent of institutions have written guide-
lines for stress ulcer prophylaxis, with approximately half
of those stating that their guidelines have been reviewed
146 Critical Care 1999, Vol 3 No 6
Table 1
Stress ulcer prophylaxis in ICU and non-ICU settings
Percentage of patients
Percentage of
institutions stating that: 0–25 26–50 51–75 76–100
ICU patients received 0 7 17 76
stress ulcer prophylaxis
Non-ICU patients received 34 44 19 3
stress ulcer prophylaxis
Patients discharged from 35 32 23 10
the ICU to non-ICU settings
remained on stress ulcer prophylaxis
ICU, intensive care unit.or updated within the past 2 years. Of responders 40% are
either considering or developing guidelines for their
respective institutions.
Fifty-eight per cent of institutions stated that there is one
preferred medication for stress ulcer prophylaxis. For those
institutions, histamine-2-antagonists were the most popular
in 77%. Sucralfate was the agent of choice in 20%, whereas
omeprazole was preferred in 3%. Antacids were not the
agents of choice in any institution. A breakdown of the
route of administration for each agent is listed in Table 3.
Ten per cent of institutions evaluated the incidence of
clinically important bleeding, which was defined as the
need for transfusion or hemodynamic changes that are
associated with bleeding. It is unclear whether these insti-
tutions limited their evaluation to patients receiving stress
ulcer prophylaxis due to the limited number of respon-
dents who answered that question (n=13). Twenty-three
per cent routinely used gastric pH measurements (ie pH
paper, pH sensor, gastric tonometry) for monitoring pH-
altering agents when such measurements were feasible.
Discussion
As indicated by the results of this survey, stress ulcer pro-
phylaxis is used in the majority (86%) of critically ill patients.
Although it is difficult (if not impossible) for any survey to
elucidate the reasons why physicians prescribe the way they
do, it is possible to hypothesize from the results of our ques-
tionnaire. For most clinicians, it appears that the presumed
benefits of prophylaxis outweigh its associated risks and
costs. Consistent with a small percentage of individuals
returning the surveys, however, there are clinicians who
believe the value of prophylaxis is overstated and question
its widespread use. This opinion is based on the perception
that the incidence of bleeding is rare, and when it does occur
it is readily amenable to endoscopic or medical therapies [3].
The number of patients receiving stress ulcer prophylaxis
in non-ICU settings is concerning. Of institutions sur-
veyed 22% stated that stress ulcer prophylaxis is given to
patients in non-ICU settings more than 50% of the time.
Also, patients discharged from ICU to non-ICU settings
remain on stress ulcer prophylaxis more than 50% of the
time in 33% of institutions. Given the lack of published
literature in non-ICU settings, along with the low risk of
clinically important bleeding, many experts believe that
routine prophylaxis is not warranted. 
The incidence of stress-induced bleeding has varied con-
siderably, depending on the definition of bleeding and the
population under study. Both microscopic and macro-
scopic (ie overt) bleeding are relatively common findings
in published studies, but there is no well documented
relationship between such bleeding and the incidence of
clinically important bleeding complications (eg hemody-
namic instability, perforation, need for transfusion).
Unfortunately, the actual incidence of clinically important
bleeding associated with many published investigations is
not available, particularly in those published before 1990.
In randomized trials conducted since 1990 that enrolled at
least 100 general medical/surgical ICU patients, the inci-
dence of clinically important bleeding associated with no
prophylaxis has ranged from 3.5 to 22.9% [4,5]. In this
survey, only 10% of the surveyed institutions evaluated
the incidence of clinically important bleeding.
Certain types of defined or single-system injuries appear
to be associated with a higher incidence of bleeding, on
the basis of retrospective data. In the present study, the
great majority of patients with head, spinal cord, thermal,
or hepatic injuries were routinely given prophylaxis. Using
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Table 2
Specialized populations where stress ulcer prophylaxis is
routinely administered
Do not have
Stress ulcer Stress ulcer substantial
prophylaxis prophylaxis numbers of
Injury is given is not given this injury
Head injury 110 3 30
Spinal cord injury 99 4 39
Thermal injury 61 3 71
Multiple trauma 106 3 34
Hepatic injury with 67 9 62
need for partial resection
Data are expressed as number of institutions responding to the
question (not percentages).
Table 3
Description of the route of administration for each institutions
preferred agent
Agent Administration route n
Histamine-2-antagonist Intermittent IV 63
IV infusion 13
Oral 27
Feeding tube 36
Sucralfate Oral 13
Nasogastric tube 20
Omeprazole Oral 4
Nasogastric tube 4
Enteral tube 2
Other 0
Responders were permitted to check more than one administration
route for their institution’s preferred agent. IV, intravenous.thermal injury as an example, however, only one random-
ized trial has been conducted, the results of which were
published in 1976 [6]. In that trial, 29.2% of patients not
receiving prophylaxis had clinically important bleeding,
compared with 4.2% of patients receiving antacid prophy-
laxis (P<0.02). Using adult patients with head injuries
(Glasgow Coma Scores £10) as another example, one trial
published in 1993 (n = 167) [7] found no instances of clini-
cally important bleeding with either saline placebo or rani-
tidine, whereas another trial published in 1995 (n=34) [8]
found that 27.8% of patients receiving no prophylaxis had
clinically important bleeding compared with none of the
patients in the ranitidine group (P£0.05).
Some of the variation in bleeding rates in published
studies may be attributable to the definition used for
delineating patients at risk for stress-induced complica-
tions. Two risk factors have been found to be predictive of
clinically important bleeding using multivariate analytic
techniques in a large sample of mixed medical/surgical
patients [9]. These risk factors are respiratory failure
requiring mechanical ventilation, and coagulopathy. It is
unknown whether these findings are applicable to more
homogeneous, specialized populations (eg patients with
burns or trauma, or patients undergoing central nervous
system surgery) because of lack of study inclusion or
insufficient enrolment numbers.
Once the decision is made to use prophylaxis, there are
several medications available. In the present investigation,
77% of the institutions surveyed used histamine-2-antago-
nists as the agent of choice, whereas 20% used sucralfate.
These percentages are similar to the findings in another
survey of stress ulcer prophylaxis in which histamine-2-
antagonists were used in 67% of patients compared with
24% of patients receiving sucralfate [10]. The majority of
published studies using clinically important bleeding as an
end point have involved histamine-2-antagonists and
sucralfate. The most comprehensive meta-analysis [1]
found no substantial differences in clinically important
bleeding between the latter agents, whereas the most
recent and largest randomized trial [2] suggested that rani-
tidine was more efficacious than sucralfate (at least with
the doses used in the trial). Trials involving other agents
such as the proton pump inhibitor omeprazole have either
not used clinically important bleeding as an end point or
lacked sufficient power to detect potential differences in
bleeding between other agents or when compared with
placebo. Given the similar type of action (inhibition of
acid release) between histamine-2-antagonists and proton
pump inhibitors, it seems likely that the pump inhibitors
would have similar efficacy.
Given the inconsistent results of published investigations,
it is perhaps not surprising that almost all aspects of stress
ulcer prophylaxis remain controversial. Until some of the
issues are resolved through further study, there are a few
recommendations that seem in order. First, it seems that
clinicians should aim for some form of consistency based
on intra-institutional guidelines using the most current,
best evidence of prophylactic benefit with histamine-2-
receptor antagonists. A majority of institutions surveyed
(73%) had no guidelines in place. Of those that did have
guidelines, almost half (48%) had not been updated in the
2 years before receiving the survey. This finding is of
concern, because the most comprehensive meta-analysis
[1] and largest randomized study [2] to date concerning
stress ulcer prophylaxis were published in the 2 years pre-
ceding the survey. This finding could be misleading,
however, because it is possible that the results of these
recent publications did not require an alteration in the
institution’s guidelines.
Institutions contemplating the development of stress ulcer
prophylaxis guidelines should take advantage of existing
information. One organization, the American Society of
Health-System Pharmacists, has recently promulgated
guidelines for stress ulcer prophylaxis that could be used as
a template for the intra-institutional development process
[11]. The American Society of Health-System Pharmacists
guidelines have an economic model that can be modified
using local efficacy, toxicity, and cost information.
There is another large survey that has been published
concerning stress ulcer prophylaxis [10]. That survey,
however, was conducted in October 1995, which was
before the publication of the largest meta-analysis [1] and
largest randomized controlled trial [2] to date. The present
survey was conducted in the fall of 1998, with one inten-
tion of determining how those reports may have influ-
enced prescribing habits. A second difference relates to
the sample of clinicians being surveyed. The previous
study [10] selected a random sample of the members of
the Society of Critical Care Medicine who identified anes-
thesiology, surgery, or internal medicine as their specialty
area. The survey response rate was 26%. Our survey was
sent to the entire Section of Pharmacy and Pharmacology
of the Society of Critical Care Medicine, and had a
response rate of 42%.
Another recommendation is to review stress ulcer prophy-
laxis prescribing periodically, as well as any guidelines that
are in place. Both published literature and local evalua-
tions may necessitate a change in the guidelines. There
are examples in the literature of where guideline changes
relative to stress ulcer prophylaxis have resulted in
lowered institutional costs without compromising the
quality of patient care [12].
A final recommendation applies to those individuals who
have the capabilities of performing clinical studies con-
cerning stress ulcer prophylaxis. Although it seems
148 Critical Care 1999, Vol 3 No 6unlikely that another study involving general medical/sur-
gical patients would resolve the debate concerning the
need for prophylaxis, randomized studies involving spe-
cialized populations (eg trauma patients) could be of
potential value, given the relative lack of controlled inves-
tigations. Also, comparative studies involving newer med-
ications and different routes of administration are needed
that use clinically important bleeding as an end point.
Although the results of this survey describe some of the
current prescribing practices of physicians in the USA rel-
ative to stress ulcer prophylaxis, there are important limi-
tations to the information presented. Some of the
limitations concern questionnaires in general. For
example, there are concerns regarding the number and
type of questions. If the instrument contains an excessive
number of questions, the responder may be less willing to
complete and return the material. This survey was limited
to one page, front and back, in an attempt to increase com-
pliance. Another concern in common with all question-
naires relates to the reliability and validity of the
instrument, although attempts were made to reduce such
problems during the instrument construction process.
Other limitations of these results pertain to the topic at
hand (ie stress ulcer prophylaxis). Physician prescribing
and guideline development are affected at different times
and to varying degrees by published trials. The largest
randomized trial comparing ranitidine and sucralfate for
stress ulcer prophylaxis was published in March 1998 [2].
This survey was mailed approximately 6 months after that
publication. Therefore, physician prescribing and institu-
tional guidelines may not have changed as a result of that
trial at the time of the present survey. Additionally, the
responses to the survey questions are a function of the
person completing the survey. Because the individuals
completing the survey were members of the Section of
Pharmacy and Pharmacology of the Society of Critical
Care Medicine, it was presumed that they were well
versed in the area of stress ulcer prophylaxis issues at their
institutions.
Conclusion
There are wide variations in prescribing practices with
regard to stress ulcer prophylaxis, although such prophy-
laxis is used in the majority of ICU patients. Histamine-2-
antagonists, sucralfate, and proton pump inhibitors are
commonly used agents, with histamine-2-antagonists
being the most commonly preferred agent among the
institutions surveyed. Published literature and available
guidelines should be used as a template for institutions
that are constructing their own guidelines.
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